Accuris Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance) TR 56

Description

Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance)

Accuris

Request a Quote

Email Supplier

Description

Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance)

Request a Quote

Email Supplier

Suppliers

Company

Product

Description

Supplier Links

Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance) - TR 56 - Accuris

Accuris

Englewood, CO, United States

Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance)
TR 56

Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance) TR 56

Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance)

Buy Now

Technical Specifications

	Accuris
Product Category	Standards and Technical Documents
Product Number	TR 56
Product Name	Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance)